We previously showed that the highly sulfated domains of heparan sulfate mediated the cell uptake of cancer cell-derived p53 aggregates and that heparin, a structural analogue of highly sulfated domains of heparan sulfate, competitively inhibited cell uptake of p53 aggregates. The gene discussed is TP53; the disease is cancer.